Workflow
BioXcel Therapeutics(BTAI)
icon
Search documents
BioXcel Therapeutics(BTAI) - 2019 Q2 - Earnings Call Transcript
2019-08-10 20:58
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2019 Results Conference Call August 6, 2019 8:30 AM ET Company Participants Vimal Mehta - CEO Richard Steinhart - CFO Frank Yocca - Chief Scientific Officer Vincent O'Neill - SVP & Chief Medical Officer Conference Call Participants Andrea Brettler - UBS Edward White - H.C. Wainwright Operator Good morning, and welcome to BioXcel Therapeutics Second Quarter 2019 Earnings Conference Call and Audio Webcast. Before we start, I would like to inform you that this confer ...
BioXcel Therapeutics(BTAI) - 2019 Q2 - Quarterly Report
2019-08-06 13:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82‑1386754 (Sta ...
BioXcel Therapeutics(BTAI) - 2019 Q1 - Quarterly Report
2019-05-07 20:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc (Exact Name of Registrant as Specified in its Charter) Delaware 82‑1386754 (Sta ...
BioXcel Therapeutics(BTAI) - 2018 Q4 - Annual Report
2019-03-11 22:28
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 001‑38410 BioXcel Therapeutics, Inc (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdic ...